P PRIMESTOCKFINDER.COM

RAD Shares Radiopharm Theranostics Limited

ASX · ASX
$0.01 +11.11% Prices as of close 2026-10-26

Last in our picks 2026-10-22 — not in the current list; analysis below is from that screen

Radiopharmaceutical pipeline expansion offers substantial optionality across oncology imaging and treatment.

Signal breakdown

  • ▸Pipeline advancement and growing radiopharmaceutical investment theme.
  • ▾Below 50-day MA (-48.39%)
  • ▾Near 52-week low (1.5% of range)

Is RAD a buy right now?

Trend: RAD is trading below the 50-day average (-50.00%), RSI 48 — neutral momentum, with a 3-month return of -64.29%.

Valuation & quality: Radiopharm Theranostics Limited trades on forward P/E -0.3, price-to-book 0.71; fundamentals show net margin 0.0%, return on equity -174.7%, revenue growth -36.9% year on year.

Analyst consensus: 1 analysts have a mean 12-month price target of A$0.15 (+2831.6% vs the last close; range A$0.15 – A$0.15), consensus rating “none”.

Our screen: WATCH (score 0) — Radiopharmaceutical pipeline expansion offers substantial optionality across oncology imaging and treatment.

Computed from end-of-day data; not personal advice.

12-month price chart

0.02 0.00 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 0.00 – 0.02.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
+0.00%+0.00%+0.00%+0.00%-50.00%+0.00%+0.00%-100.00%

Fundamentals

Market cap
$21.9M
P/E (ttm)
-0.3
Forward P/E
-0.3
EPS (ttm)
$-0.02
Price / book
0.71
Beta
0.86
Net margin
0.0%
ROE
-174.7%
Revenue growth
-36.9%
Revenue (ttm)
$12.9M
Free cash flow
$-31,142,938
52-wk range
$0.00 – $0.04
Volume
2,918,823
Avg volume (3m)
9,269,538

Analyst price target

Mean target
$0.15
Low
$0.15
High
$0.15
Analysts
1
Consensus
NONE

Technical signals

RSI (14)
48.0
vs 50-day MA
-50.00%
1-mo return
-28.57%
3-mo return
-64.29%
Volume z-score
-0.52

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States.

Sector: Healthcare · Industry: Biotechnology · Australia · 14 employees · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.